XML 39 R26.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Concentrations | 12 Months Ended
--- | ---
Dec. 31, 2017
Concentrations [Abstract] |
CONCENTRATIONS |
20. | CONCENTRATIONS
Major Customers For the years ended December 31, 2017, 2016, and 2015, approximately 56%, 94%, and 7% of the Company’s revenues from continuing operations were derived from two major customers. For the years ended December 31, 2016, and 2015, approximately 96%, and 61% of the Company’s total revenues from discontinued operations were derived from two major customers. Major Suppliers For the years ended December 31, 2017, 2016 and 2015, purchases from three major suppliers were approximately 65%, 98% and 87% of the total purchase from continuing operations, respectively. For the years ended December 31, 2016, and 2015, purchases from three major suppliers were approximately 94 % and 78% of the total purchase from discontinued operations, respectively. Revenues by products The following represents the revenues by product line, all derived from China:
|  | For the years ended December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
Products Line |  |  |  |  |  |  |  |  |
Medical Devices |  | $ | 827,032 |  |  | $ | 1,305,372 |  |  | $ | 1,500,957 |
Respiratory and Oxygen Homecare |  |  | - |  |  |  | 5,956 |  |  |  | 20,573 |
Mobile Medicine (sleep apnea diagnostic products) |  |  | 54,979 |  |  |  | 12,080,164 |  |  |  | 164,503 |
Total Revenues |  |  | 882,011 |  |  |  | 13,391,492 |  |  |  | 1,686,033 |
Less: revenues from discontinued operations |  |  | - |  |  |  | (329,119 | ) |  |  | (947,732 | )
Revenues from continuing operations |  | $ | 882,011 |  |  | $ | 13,062,373 |  |  | $ | 738,301 |

X
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI http://asc.fasb.org/topic&trid=2134479 + Details
Name: | us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration